Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Price Down 6% – Time to Sell?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)’s share price dropped 6% during trading on Tuesday . The stock traded as low as $23.74 and last traded at $23.7340. 249,300 shares changed hands during trading, a decline of 63% from the average daily volume of 675,643 shares. The stock had previously closed at $25.26.

Analysts Set New Price Targets

A number of research firms recently weighed in on FMS. Weiss Ratings lowered shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Citigroup reissued a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, July 17th. Wall Street Zen lowered shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Zacks Research raised shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Wednesday, May 6th. Six research analysts have rated the stock with a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $23.95.

Fresenius Medical Care AG & Co. KGaA Stock Down 5.1%

The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.86 and a current ratio of 1.20. The stock has a market capitalization of $12.88 billion, a PE ratio of 12.62, a PEG ratio of 4.56 and a beta of 0.77. The business has a 50 day moving average of $23.39 and a two-hundred day moving average of $22.96.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its earnings results on Monday, August 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.90% and a net margin of 4.88%.The company had revenue of $5.55 billion for the quarter, compared to analyst estimates of $5.49 billion. Analysts predict that Fresenius Medical Care AG & Co. KGaA will post 2.22 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of FMS. Morgan Stanley increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 47.2% during the fourth quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock worth $70,027,000 after purchasing an additional 942,497 shares in the last quarter. Pzena Investment Management LLC boosted its position in shares of Fresenius Medical Care AG & Co. KGaA by 2.0% in the 1st quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company’s stock worth $339,592,000 after purchasing an additional 299,986 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Fresenius Medical Care AG & Co. KGaA by 279.7% in the 2nd quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock worth $9,637,000 after purchasing an additional 248,477 shares in the last quarter. ABC Arbitrage SA grew its stake in Fresenius Medical Care AG & Co. KGaA by 1,136.0% during the 4th quarter. ABC Arbitrage SA now owns 249,800 shares of the company’s stock worth $5,950,000 after buying an additional 229,589 shares during the last quarter. Finally, Integral Health Asset Management LLC grew its stake in Fresenius Medical Care AG & Co. KGaA by 44.4% during the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $15,483,000 after buying an additional 200,000 shares during the last quarter. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.